Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in com...

Descripción completa

Detalles Bibliográficos
Autores principales: Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, M O, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A, Vitale, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823224/
https://www.ncbi.nlm.nih.gov/pubmed/21883896
http://dx.doi.org/10.1111/j.1582-4934.2011.01438.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823224/
https://www.ncbi.nlm.nih.gov/pubmed/21883896
http://dx.doi.org/10.1111/j.1582-4934.2011.01438.x

Ejemplares similares